Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 3
2018 1
2019 2
2020 1
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

8 results
Results by year
Filters applied: . Clear all
Page 1
Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.
Dunn LA, Sherman EJ, Baxi SS, Tchekmedyian V, Grewal RK, Larson SM, Pentlow KS, Haque S, Tuttle RM, Sabra MM, Fish S, Boucai L, Walters J, Ghossein RA, Seshan VE, Ni A, Li D, Knauf JA, Pfister DG, Fagin JA, Ho AL. Dunn LA, et al. Among authors: tchekmedyian v. J Clin Endocrinol Metab. 2019 May 1;104(5):1417-1428. doi: 10.1210/jc.2018-01478. J Clin Endocrinol Metab. 2019. PMID: 30256977 Free PMC article.
SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies.
Saqcena M, Leandro-Garcia LJ, Maag JLV, Tchekmedyian V, Krishnamoorthy GP, Tamarapu PP, Tiedje V, Reuter V, Knauf JA, de Stanchina E, Xu B, Liao XH, Refetoff S, Ghossein R, Chi P, Ho AL, Koche RP, Fagin JA. Saqcena M, et al. Among authors: tchekmedyian v. Cancer Discov. 2021 May;11(5):1158-1175. doi: 10.1158/2159-8290.CD-20-0735. Epub 2020 Dec 14. Cancer Discov. 2021. PMID: 33318036
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.
Gibson CJ, Lindsley RC, Tchekmedyian V, Mar BG, Shi J, Jaiswal S, Bosworth A, Francisco L, He J, Bansal A, Morgan EA, Lacasce AS, Freedman AS, Fisher DC, Jacobsen E, Armand P, Alyea EP, Koreth J, Ho V, Soiffer RJ, Antin JH, Ritz J, Nikiforow S, Forman SJ, Michor F, Neuberg D, Bhatia R, Bhatia S, Ebert BL. Gibson CJ, et al. Among authors: tchekmedyian v. J Clin Oncol. 2017 May 10;35(14):1598-1605. doi: 10.1200/JCO.2016.71.6712. Epub 2017 Jan 9. J Clin Oncol. 2017. PMID: 28068180 Free PMC article.
Targeting VEGF and EGFR: a combination worth re-exploring?
Tchekmedyian V, Sherman EJ. Tchekmedyian V, et al. Lancet Oncol. 2018 Aug;19(8):1007-1009. doi: 10.1016/S1470-2045(18)30377-2. Epub 2018 Jul 11. Lancet Oncol. 2018. PMID: 30001988 No abstract available.
Brain MRS glutamine as a biomarker to guide therapy of hyperammonemic coma.
O'Donnell-Luria AH, Lin AP, Merugumala SK, Rohr F, Waisbren SE, Lynch R, Tchekmedyian V, Goldberg AD, Bellinger A, McFaline-Figueroa JR, Simon T, Gershanik EF, Levy BD, Cohen DE, Samuels MA, Berry GT, Frank NY. O'Donnell-Luria AH, et al. Among authors: tchekmedyian v. Mol Genet Metab. 2017 May;121(1):9-15. doi: 10.1016/j.ymgme.2017.03.003. Epub 2017 Mar 10. Mol Genet Metab. 2017. PMID: 28408159
Any day, split halfway: Flexibility in scheduling high-dose cisplatin-A large retrospective review from a high-volume cancer center.
Kang JJ, Tchekmedyian V, Mohammed N, Rybkin A, Kitpanit S, Fan M, Wang H, Lobaugh SM, Zhang Z, Lee A, Chen L, Yu Y, Zakeri K, Gelblum DY, Riaz N, McBride SM, Tsai CJ, Cohen MA, Cracchiolo JR, Morris LG, Singh B, Patel S, Ganly I, Boyle JO, Wong RJ, Eng J, Zhi WI, Ng K, Ho AL, Dunn LA, Michel L, Fetten JV, Pfister DG, Lee NY, Sherman EJ. Kang JJ, et al. Among authors: tchekmedyian v. Int J Cancer. 2021 Jul 1;149(1):139-148. doi: 10.1002/ijc.33518. Epub 2021 Feb 27. Int J Cancer. 2021. PMID: 33586179